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TIIVISTELMÄ 
 
Tutkimuksen tausta ja tavoitteet: Eturauhassyöpä on yksi yleisemmistä syövistä 
maailmanlaajuisesti ja vaikuttaa miljoonien miesten elämään. Molekulaariset 
mekanismit, jotka vaikuttavat eturauhassyövän taustalla, ovat edelleen melko huonosti 
tunnettuja. Genomin kopiolukumuutokset ja geenien fuusiot ovat yleisiä 
eturauhassyövässä ja esimerkiksi TMPRSS2-ERG geenifuusio on tunnettu ja yleinen 
eturauhassyövän alatyyppi. Aiemmin löysimme TMPRSS2-SKIL geeni fuusion 
eturauhassyöpäpotilaalta otetusta kliinisestä näytteestä. Samalta potilaalta ei löydetty 
muita tunnettuja ETS geenien fuusioita. Tämä viittaa siihen, että tässä tapauksessa 
TMPRSS2-SKIL fuusio voi olla syynä syövän kehittymiseen. Tämän tutkimuksen 
tavoitteena oli luoda eturauhassolulinjoja, jotka yli-ilmentävät SKIL-geeniä ja tutkia 
onko tällä vaikutusta näiden solujen fenotyyppiin. 
 
Tutkimusmenetelmät: SKIL geenin sisältävä plasmidi ja kontrolliplasmidi ilman 
geeniä tilattiin Addgeneltä. DU-145 ja RWPE-1 solulinjat transfektoitiin joko SKIL-
plasmidilla tai kontrolliplasmidilla. Molempia solulinjoja kasvatettiin mediumissa, joka 
sisälsi geneticin® selektiivistä antibioottia (Gibco). Selektion jälkeen DU-145 soluista 
tehtiin yksisoluklooneja käyttäen erittäin laimeaa (solua/ml) soluliuosta. Sekä mRNA 
että proteiinit kerättiin molemmista solulinjoista. Kerättyä mRNA:ta käytettiin RT-
qPCR:ään ja proteiineja western blottaukseen. Proliferaatiota tutkittiin mikroskoopin ja 
digitaalikuva-analyysin avulla. Invaasiota tutkittiin käyttäen BD BioCoat Matrigel 
Invasion Chambers (BD Biosciences). 
 
Tutkimustulokset: Tässä tutkimuksessa loimme solulinjoja, joissa on stabiilisti 
transfektoituna SKIL-plasmidi ja kontrolliplasmidi. Osoitimme, että SKIL on yli-
ilmentynyt mRNA tasolla solulinjoissa, DU-145 yksisoluklooneissa ilmenemistasot 
tosin vaihtelivat suuresti. Yli-ilmenemistä ei voitu osoittaa proteiinitasolla 
kummassakaan solulinjassa. Osoitimme, että SKIL:n yli-ilmeneminen ei aiheuta 
proliferaatio eroja, mutta se lisää invaasiota RWPE-1 soluissa ja joissain DU-145 
klooneissa. 
 
Johtopäätökset: Tuloksemme osoittivat, että SKIL:n yli-ilmentyminen pystyy 
aiheuttamaan erilaisen fenotyypin käytetyissä solulinjoissa. Pystyimme osoittamaan 
selvän eron RWPE-1-soluissa ja osassa DU-145 klooneja. Tämä viittaa siihen, että 
SKIL:n yli-ilmeneminen saattaa yksistään olla tarpeeksi aiheuttamaan eturauhassyövän 
kasvua. Proteiinitason yli-ilmenemisen puuttuminen jättää kuitenkin kysymyksen 
fenotyypin aiheuttavasta mekaniikasta. Lisää tutkimusta tarvitaan, että saadaan selville 
SKIL:n tarkka rooli eturauhassyövässä ja sen kehittymisessä.   
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ABSTRACT  
 
Background and aims: Prostate cancer is among the most common malignancies in 
the world affecting millions of men worldwide. Molecular mechanisms behind the 
prostate cancer are still poorly understood. Genomic copy-number alterations and gene 
fusions are common in prostate cancer and for example TMPRSS2-ERG gene fusion is 
one of the common known subtypes of prostate cancer. Previously we found TMPRSS2-
SKIL gene fusion from clinical sample collected from prostate cancer patient. This 
patient was also negative for ETS fusions so this predicts that this cancer may be caused 
by TMPRSS2-SKIL gene fusion. The aim of this study was to generate prostate cancer 
cell lines with stable SKIL overexpression and to investigate whether SKIL 
overexpression would have any effect on the phenotype of the cells. 
 
Methods: Plasmid with SKIL and control plasmid without it were ordered from 
Addgene. DU-145 and RWPE-1 were transfected either with SKIL plasmid or with 
control plasmid. Then cell were let to grow with geneticin® selective antibiotic (Gibco) 
to select only the cells with plasmid. With DU-145 cells after selection single cell clones 
were created by using very low cells/ml dilution. Both mRNA and proteins were 
collected from both cell lines and RT-qPCR were performed for mRNAs and western 
blotting for proteins. Proliferation assays were performed for both cell lines using 
microscopy and digital image analysis. Invasion assays were performed for both cell lines 
using BD BioCoat Matrigel Invasion Chambers (BD Biosciences).  
 
Results: In this study we created cell lines with stable transfections of SKIL and control 
plasmid. We showed that SKIL is overexpressed in mRNA level when compared to 
control cells. Expression levels were differentiating quite a lot between DU-145 single 
cell clones. However we failed to show that this expression is also carried to protein 
level (in both DU-145 and RWPE-1 cells). We showed that SKIL overexpression does 
not induce any proliferation difference but it induces invasion in RWPE-1 cells and 
with some DU-145 clones.  
 
Conclusion: Our results showed that it is possible for SKIL overexpression to induce 
different phenotype for cell lines used. In this case there was clear difference with 
RWPE-1 cells and with some DU-145 cells. This indicates that it is be possible that 
SKIL overexpression alone could induce prostate cancer growth. However there were 
no clear SKIL overexpression in protein level and this leaves questions about 
mechanisms which cause the phenotype. Further investigations needs to be carried out 
to find out precise functions of SKIL and it’s overexpression in prostate cancer.  
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ABBREVIATIONS 
 
 
ABL1    Abelson murine leukemia viral oncogene homolog  
AKT    Protein kinase B 
AR    Androgene receptor 
BCR    Breakpoint cluster region protein 
BMI    Body mass index 
BPE    Bovine pituitary extract 
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DTT    Dithiothreitol 
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EGF    Epidermal growth factor 
ELAC2   ElaC Ribonuclease Z 2 
EP156T   EP156T human prostate cancer cell line 
ERG    ETS-related gene 
ERVK-24   Endogenous Retrovirus Group K, Member 24 
ETS    ETS transcription factor family 
ETV1/4/5   ETS translocation variant 1/4/5 
FLI1    Friend leukemia integration 1 transcription factor 
G418    Geneticin 
HDAC    Histone deacetylases 
Hep3B    Hep3B human hepatoma cell line 
HES6    Transcription cofactor HES-6 
HNRPA2B1   Heterogeneous nuclear ribonucleoproteins A2/B1 
Hox    Paralogous homeobox 
H3K18Ac   Histone H3 acetyl Lys18 
H3K4    Histone H3 lysine 4 
LNCaP   LNCaP human prostate cancer cell line 
LuCaP    LuCaP Series of Prostate Cancer Xenografts  
MIPEP   Mitochondrial intermediate peptidase 
mSin3A   mSin3A chromatin modifying complex 
MSR1    Macrophage scavenger receptor 1 
MYC    c-Myc 
N-CoR    nuclear receptor co-repressor 1 
NDRG1   N-Myc Downstream Regulated 1 
NKx3.1   Homeobox protein Nkx-3.1 
PC-3    PC-3 human prostate cancer cell line 
PIN    Prostatic intraepithelial neoplasia 
PI3K    Phosphatidylinositol-4,5-bisphosphate 3-kinase 
PSA    Prostate-specific antigene 
PTEN    Phosphatase and tensin homolog 
RB1    Retinoblastoma protein 
RNASEL   Ribonuclease L 
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RT-qPCR   Real time quantitive reverse transcription PCR 
RWPE-1   RWPE-1 epithelial cells 
SKIL    SKI-like proto-oncogene  
SLC45A3   Solute carrier family 45 member 3 
SMRT    Nuclear Receptor Corepressor 2 
TGF-β    Transforming growth factor beta 
TMPRSS2   Transmembrane protease serine 2 
TOP2B   DNA topoisomerase 2-beta 
TP53    Tumor protein p53 
VDR    Vitamin D receptor 
22RV1    22RV1 human prostate cancer cell line 
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1. INTRODUCTION 
 
Prostate cancer is second most common cancer among the men worldwide and most 
common cancer in western countries (Center et al. 2012). It is also sixth leading cause 
of cancer deaths worldwide (Center et al. 2012). It is known that prostate cancer 
incidence increases with the age and as the life expectancy is increasing, especially in 
the western countries, the rate of new prostate cancer cases is likely to go up in the 
future (Center et al. 2012). Although cases are increasing the mortality rate is 
decreasing which is mostly due the better treatment options (Center et al. 2012). 
 
Prostate cancer is known to be highly heterogeneous disease, both clinically and 
genetically (Boyd et al. 2012). Fortunately most of the tumors in prostate are slowly 
growing, metastasize poorly and are not likely to cause death (Boyd et al. 2012). There 
are however prostate cancers which have aggressive behavior and can metastasize 
(Boyd et al. 2012). This provides the problem to identify aggressive and non-aggressive 
cancers from each other and indeed there are many alterations in prostate cancer which 
are known to cause aggressive phenotype (Boyd et al. 2012).  
 
Among the known alterations are gene fusions such as TMPRSS2-ETS fusions (Boyd 
et al. 2012). This fusion means that ETS genes are brought under the promoter of 
TMPRSS2 and this usually causes increased expression patterns of ETS genes (Boyd et 
al. 2012). Especially important fusion is TMPRSS2-ERG fusion which is not only the 
most recurrent TMPRSS2-ETS but there is also evidence that there is an association 
between the presence of this fusion and the outcome of the cancer (Boyd et al. 2012).  
 
Previously novel TMPRSS2-SKIL fusion was found from single patient with prostate 
cancer (Annala et al. 2015). This patient also had no other common alterations known 
to be present in prostate cancer so this lead to hypothesis that cancer may be caused by 
TMPRSS2-SKIL fusion (Annala et al. 2015). Effects of SKIL overexpression could 
provide more information about role and mechanisms of SKIL in prostate cancer. Also 
there is no previous studies about SKIL overexpression in prostate cancer cells. In light 
of the found TMPRSS2-SKIL fusion it is important to find the functions of SKIL in 
prostate cancer cells. 
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2. REVIEW OF LITERATURE 
 
2.1 Prostate 
 
Prostate gland is part of the male reproductive system. It has roles in the production and 
transportation of ejaculate and male sex hormones. Main function of prostate is to 
secrete and store the slightly alkaline, milky prostatic fluid, which constitutes about half 
of the semen volume, along with the spermatozoa and seminal vesicle fluid.  
 
The prostate is derived from the primitive endoderm, which first differentiates to cloaca. 
This happens during the embryogenesis. After this in humans the cloaca separates to 
digestive outlet and urogenital sinus, which in turns segments into the urinary bladder 
and the urethra (Berman et al. 2012). Then prostate can develop via the proliferation of 
epithelial buds from the urogenital sinus epithelium. After this these buds invade 
according to particular pattern, which directs the future development of distinct prostate 
zones (or lobes which happens e.g. in mice). Later on urogenital sinus mesenchymal 
cells can differentiate into stromal elements. Prostate budding occurs during the 10th 
week of embryogenesis (Berman et al. 2012). 
 
Primary motivating force driving the prostate development, is androgen receptor (AR) 
signaling, which acts on the mesenchyme. This said it is important to notice that AR 
signaling only affects the timing of the events and has no effects on the location of 
events. This means that AR doesn’t decide where prostate starts to develop (Podlasek 
et al. 1997). The mechanisms which direct the precise locations of prostate epithelial 
buds are not fully understood. However there are evidences which predict that it is 
related to paralogous homeobox (Hox) genes, as they coordinate similar processes in 
various tissues. Also mutations in Hox genes can result to changes in the prostatic 
branching patterns (Podlasek et al. 1997). 
 
The prostate tissue in the adults is a complex tubule-alveolar gland. The regional 
anatomy of prostate was under the debate during the latter half of 20th century. 
Originally prostate was classified into lobes, but nowadays this concept is commonly 
replaced by zonal model. This model divides prostate into anterior, peripheral, central 
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and transitional zones that all have their own architectural features. Prostate is 
composed of epithelial and stroma. In epithelial compartment there is basal epithelial 
cells, intermediate cells, neuroendocrine cells and luminal secretory cells. Stromal 
compartment services more as a supportable structure and is consisted mostly from 
connective tissue, smooth muscle cells and fibroblasts (Berman et al. 2012).  
 
As said androgen signaling is really important during the development of the prostate 
in embryogenesis but it remains important during the different stages of human life and 
has a role in the growth, maintenance and secretory function of prostate. In cell level 
androgens normal function is to drive cell differentiation (Berman et al. 2012).  
 
2.2 Prostate cancer 
 
2.2.1 Epidemiology  
 
Prostate cancer is the most common non-skin cancer neoplasm amongst men not only 
in Europe (Bray et al. 2010) but also worldwide (Fontes et al. 2013). Also worldwide 
prostate cancer is the sixth leading cause of oncological death among men. In 2008 
approximately 250000 deaths were due to prostate cancer (Fontes et al. 2013). In 2008 
in Europe there has been almost 90000 deaths due prostate cancer (Bray et al. 2010). 
In Finland alone the mean incident cases per year was 4480 during 2001-2005. This 
means that Finland has one of the highest prostate cancer occurrence rates in Europe 
(Bray et al. 2010). Overall in northern Europe the disease rates are very high and 
unfortunately it seems that these rates are even growing. From 1990 to 1995 the increase 
percent concerning prostate cancer cases in Finland was 9,3% per year (Bray et al. 
2010). This increase in prostate cancer incidence rates is mostly due to increased life 
expectancy, advanced diagnostic methods and PSA screening (Center et al. 2012). 
Prostate cancer is disease strongly associated with aging in United States over 70 % of 
all cases are diagnosed to men over 65 years old (Crawford 2003). 
 
Also ethnicity is very high risk factor in prostate cancer. African Americans have 
among the highest rates of prostate cancer in the world. The incidence rate among 
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African Americans is 60% higher than among the white American men. Incidence rates 
are even lower among the Hispanics and Asians/Pacific Islanders (Clegg et al. 2002). 
 
However when mortality rates are being examined things don’t look that bad. During 
the past few decades the mortality rate in prostate cancer has steadily decreased. The 5-
year relative survival proportions are approaching 100% especially with the localized 
disease. This may be due the overall improvements in treatment or an effect of PSA 
testing which helps us to detect disease early enough (Bray et al. 2010).    
 
2.2.2 Risk factors 
 
There are several different risk factors related to prostate cancer. When talking about 
risk factors it needs to be made clear, which kind of risks we are talking about, because 
prostate cancer risk factors can be divided to several subgroups, such as for 
‘‘aggressive’’ and ‘‘non-aggressive’’ cancers or by grade or stage. Many times however 
this division is not clear mainly because we still have problems in recognizing if cancer 
itself is “aggressive” or “nonaggressive”.  There are three clear factors which have clear 
connection to overall incident prostate cancer risk: age, positive family history and race 
(Giovannucci et al. 2007). There are also evidence which point out that higher tomato 
sauce intake (inversely), vitamin D and α-linolenic acid intake have also association 
with overall prostate cancer risk (Giovannucci et al. 2007). Other important subtype of 
risk factor is fatal prostate cancer risk. There are several different factors that can have 
effects on this. At least recent smoking history, taller height, higher BMI, family 
history, and high intakes of total energy, calcium and α-linolenic acid were associated 
with higher risk (Giovannucci et al. 2007).  It seems the trend in United States (and 
maybe in other western countries also) is that men are diagnosed prostate cancer sooner 
than before. In the United States prostate cancers have significantly increased among 
men younger than 50 years old during the last decade. On the other hand the incidence 
rates among men older than 70 years have decreased at the same time. This suggests 
that these changes result from earlier diagnosis (Li et al. 2012).  
Even when we are not talking about hereditary prostate cancer, a family history of 
prostate cancer is known to be associated with increased risk of prostate cancer 
diagnosis (Thomas et al. 2012). There are studies which suggest that there is even 2,5-
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fold higher relative risk to prostate cancer when you are first-degree relatives of prostate 
cancer patient. This risk can increase to 3,5-fold risk when you are first-degree relatives 
of two prostate cancer patient (Johns & Houlston 2003). Also there is evidence that it 
is not only the higher risk to get prostate cancer but there is also link between disease 
outcome and family history.  Men with first-degree relatives affected by prostate cancer 
are diagnosed and die at earlier age (Brandt et al. 2009). 
 
As said race is important risk factor. In United States in 2007 black males had an age-
adjusted annual death rate from prostate cancer 2,4 times that of whites. All though this 
risk factor is well known and widely accepted the reasons behind it are not clear at all. 
White men are screened more frequently and also they are treated more frequently after 
prostate cancer diagnosis. This may be at least on factor, which explains this difference 
but even that is not perfectly clear (Taksler et al. 2012). Interestingly Asian population 
seems to have lower prostate cancer risk than men in Europe or in United States. Some, 
but not all, of this risk can be explained through environmental factors like diet. This 
however doesn’t explain the fact that when Asian men move to western countries they 
still have lower risk of getting the prostate cancer (Ito 2014). 
 
In many cancers smoking is significant risk factor but its role in the prostate cancer is 
not as clear as in some other cancers. There is however study which suggests that 
current smokers have a decreased risk of nonadvanced prostate cancer. On the other 
hand they also have increased risk of fatal prostate cancer. Former smoking also seemed 
to decrease the risk of nonadvanced prostate cancer. They didn’t find any association 
between smoking and advanced prostate cancer (Watters et al. 2009). In another study 
which was carried out as an observational study, they found out that smoking in the 
time of prostate cancer diagnosis increased overall mortality and cardiovascular disease 
and prostate cancer specific mortality and cancer recurrence. In this study also they 
found out that if men had stop smoking at least 10 years ago they had same risk for 
cancer-specific mortality as those never smoked (Kenfield et al. 2011). 
 
Another common habit: consumption of alcohol has also role in risks associated to 
prostate cancer. There are several studies available about the subject but results are 
inconsistent. Cohort study in United State suggests that risk of nonadvanced prostate 
cancer is increased upon the increase of alcohol usage but there is no increased risk 
 14 
 
between alcohol usage and advanced prostate cancer (Watters et al. 2010). In another 
study carried out in New Zealand results were just the opposite and they sat that 
consumption of alcohol lowers the risk of getting prostate cancer of any kind 
(Karunasinghe et al. 2012). In third research the outcome was that there is no difference 
what so ever if one consumes alcohol or not. This was true even with larger amounts of 
alcohol (Rota et al. 2012).  
 
Vitamin D is known to have effects in preventing prostate cancer (Wang & Tenniswood 
2014). There is data which demonstrates an inverse association between serum vitamin 
D3 levels, cancer incidence and related mortality. There is studies which suggest that 
vitamin D3 induces apoptosis of androgen dependent prostate cancer cell lines. Other 
studies on the other hand suggest that D3 only induces cell cycle arrest. Mechanism 
behind the vitamin D functions are not clear but recent studies have found synergistic 
crosstalk between the vitamin D- and androgen-mediated mRNA and miRNA 
expression, which adds an additional layer of post-transcriptional regulation to the 
known VDR- and AR-regulated gene activation (Wang & Tenniswood 2014). 
 
There are also some other interesting risk factors which are affected by people behavior. 
Coffee consumption has been shown to decrease overall risk of getting prostate cancer. 
However this seems to be true only on high levels (Wilson et al. 2011). Controversially 
there is another study which says that there is no difference between drinkers and non-
drinkers of coffee when it comes to overall risk of prostate cancer, but even this study 
is saying that there is difference if we talk only high Gleason grade cancers (Shafique 
et al. 2012). The omega-3 fatty acid α-linolenic acid has also been attraction of many 
prostate cancer studies. Despite of this it is still not clear if this fatty acid has some role 
or not with prostate cancer. There are many studies that suggests that there might be 
small increased risk to get prostate cancer upon the high usage of α-linolenic acid. These 
studies all however highlight the fact that more studies are needed. On the other hand 
there is studies which say that there is no link between α-linolenic acid and prostate 
cancer (De Stefani et al. 2000, Brouwer et al. 2004, Koralek et al. 2006, Simon et al. 
2009). 
 
As we can see there is many different risk factors related to prostate cancer and it is not 
easy to say which ones are really relevant and which ones have more minor impacts on 
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cancer development. Studies are often controversy and often they concentrate only to 
one potential risk factor. However there is clear consensus that high age and positive 
family history are the most important risk factors when talking about prostate cancer 
(Giovannucci et al. 2007).                          
 
2.2.3 Pathogenesis 
 
Usually first thing appearing in prostate cancer is prostatic intraepithelial neoplasia 
(PIN). PINs can be divided to low grade and high grade PINs. Usually low grade PINs 
are not even reported if clinically found and when word “PIN” is mentioned it usually 
refers to high grade PIN (Bostwick & Cheng 2012). High grade PINs are more often 
than not accepted to be precursors of prostate cancer. It seems that the incidence of 
PINs increases with the age, just like with the prostate cancer. The reported high grade 
PINs of African Americans by decade of age between the third and eighth decades were 
7%, 26%, 46%, 72%, 75% and 91% (Montironi et al. 2007). Also the frequency and 
the severity of HGPIN increases in the presence of prostate cancer and it is possible to 
observe the transition of high grade PIN to prostate cancer from the morphological point 
of view (Montironi et al. 2007). PINs can be described as the progressive abnormalities 
with genotypes and phenotypes that are an intermediate of those in benign prostate 
epithelium and prostate cancer. PINs are characterized by cellular proliferation within 
ducts and acini of prostate. Abnormalities which usually occur are nuclear and 
nucleolar. Also there is inversion of the normal orientation of epithelial proliferation 
from the basal cell compartment to the luminal surface (Bostwick & Cheng 2012).  
 
Allthough PINs are kept as precursors of prostate cancer they are quite common they 
do not lead to cancer in most cases (Schoenfield et al. 2007, Gallo et al. 2008). The 
mean incidence of PIN cases is about 9%. This represents about 115 000 new cases of 
isolated PIN diagnosed each year in the United States (Bostwick & Cheng 2012).  
Another common prostate disease affecting men worldwide is benign prostate 
hyperplasia (BPH). It is a slow progressive enlargement of the prostate gland which can 
lead to lower urinary tract symptoms. This happens usually in older men. It is normally 
characterized by hyperproliferation of epithelial and stromal cells in the transition zone 
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of the prostate gland. Although BPH is a clear problem it is not usually precursor of 
prostate cancer (Prajapati et al. 2013).      
 
2.3 Prostate cancer genetics 
 
Prostate cancer is heterogeneous disease (Boyd et al. 2012, Tapia-Laliena et al. 2014). 
There can be multiple cancer loci in single prostate gland and also histologically 
identical tumors can lead to clinically different outcomes such as latent or aggressive 
disease (Boyd et al. 2012). One thing that at least partly can explain this phenomena is 
genetic heterogeneity. During past several years more and more evidence points to the 
direction that this genetic heterogeneity is caused by genetic instability. Also it seems 
that genomic instability, at least in some level, can explain biological differences 
between the aggressive and indolent prostate cancer (Boyd et al. 2012, Tapia-Laliena 
et al. 2014). Although there is clear heterogenic nature in prostate cancer, there is also 
several recent studies, which suggests that the majority of multifocal prostate cancers 
may have monoclonal origins. This is contrary to that what was previously thought 
(Lindberg et al. 2013). 
 
Heredity plays an important role in prostate cancer. However it is not perfectly clear 
how common heredity prostate cancer is. This is because the hereditary prostate cancer 
genes have not yet been cloned and the definition is based on the pedigree only. The 
prevalent definition includes nuclear families with 3 cases of prostate cancer, families 
with prostate cancer in each of 3 generations in the paternal or maternal lineage and 
families with 2 men diagnosed with the disease before age of 55 years (Bratt 2002, 
Ishak & Giri 2011). This represents about 3% to 5% of all prostate cancer cases but 
because it is difficult to identify female mutation carriers this method misses some of 
the cases. The true proportion of prostate cancer caused by mutations in dominantly 
inherited susceptibility genes with high penetrance is more likely 5% to 10% (Bratt 
2002). However this 5% to 10% represents a vast majority of early onset diseases (Bratt 
2002, Lange et al. 2012). Several genes such as RNASEL, ELAC2 and MSR1 are known 
to harbor mutations in hereditary prostate cancer. Also somatic mutations in these same 
genes usually are associated with sporadic prostate cancer (Noonan-Wheeler et al. 
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2006). But even if we are not talking about the heredity prostate cancer, positive family 
history is still most important risk factor (Boyd et al. 2012).  
 
The ever developing new techniques such as next-generation sequencing are giving us 
more and more information about genetic and genomic alterations in cancer. This 
information is highlighting the fact that genetic basis of prostate cancer is complex. 
There really isn’t any single alteration that is by itself enough to cause prostate cancer. 
It is prevalently believed that cancer is evolving through the accumulation of multiple 
alterations of genome in same cell. Mutations can be divided to driver and passenger 
mutations. Driver mutations are mutations which give cell a selective growth advantage 
compared to another cells. On the other hand the passenger mutations don’t have effect 
on the growth of the cells. According to some studies, human solid tumors typically 
contain 40-100 coding gene alterations and 5-15 of these are usually driver mutations. 
(Bozic et al. 2010). 
 
2.3.1 Chromosomal alterations 
 
There are two types of massive chromosomal-damaging events which have been 
recently found in prostate cancer: chromothripsis and chromoplexy. There is evidence 
that these events can occur as a single event. In chromothripsis there is structural 
rearrangements which occur in a clustered fashion. This involves a single chromosome 
or single arm of a chromosome with 10s to 100s of rearrangements. Chromothripsis has 
been observed in approximately in 2% to 5% of cancers so far  (Stephens et al. 2011, 
Tapia-Laliena et al. 2014). Chromothripsis has been associated to mutations in TP53 
and an aberrant DNA damage response, but it is not clear what the mechanism is behind 
this phenomena (Stephens et al. 2011). Likely explanation is the shattering of on or few 
chromosome and then rejoining them randomly by DNA repair machinery. This may 
lead to deletions of cancer suppressor genes or amplifications of oncogenes (Tapia-
Laliena et al. 2014).  
 
In chromoplexy there is generation of chained patterns of chromosomal rearrangements 
and deletion bridges which is generated from chromosomal DNA located in multiple 
chromosomes. Likely explanation why chromoplexy causes tumor progression is same 
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as with the chromothripsis: cancer suppressor gene expression is disrupted and 
oncogene gene expression is increased  (Baca et al. 2013, Tapia-Laliena et al. 2014). 
Chromoplexy is often associated with ERG rearrangements such as TMPRSS2-ERG 
fusion. This could even implicate that chromoplexy plays some role in cancer initiation 
(Baca et al. 2013). This two events are important also in that sense that they challenge 
the classical view in which cancer is developed through the accumulation of mutations 
and alterations over a prolonged period (Tapia-Laliena et al. 2014). 
 
Another common chromosomal alteration in cancer is aneuploidy which means 
numerical whole chromosome aberrations. Aneuploidy can also be found from other 
malignancies and common feature of aneuploidy is the increasing of it with stage. This 
leads to the fact that virtually all CRPCs are aneuploid (Tapia-Laliena et al. 2014). 
Aneuploidy is often driven by centrosomal abnormalities which are very common 
founding in prostate cancer. These centrosomal abnormalities can be found from 100% 
of metastatic lesions and also more than 90% of localized prostate cancer (Pihan et al. 
2001). However it is important to remember that not always centrosomal abnormalities 
lead to aneuploidy. Interestingly as with the chromoplexy the aneuploidy has also been 
linked to ERG rearrangements (Saramaki & Visakorpi 2007, Magistroni et al. 
2011)(Saramaki, Visakorpi 2007, Magistroni, Mologni et al. 2011)(Saramaki & 
Visakorpi 2007, Magistroni et al. 2011)(merged).  
 
There are also several copy number alterations (CNAs) in prostate cancer both gains 
and losses. Common losses found in prostate cancer are losses of 2q21-22, 5q13-21, 
6q14-21, 8p21-23, 10q23-25, 13q14-22, 16q13-24, 18q12-23 and 21q22. Common 
gains are the gains of 3q23-33, 7q21-33, 8q12-23, 17q24-25 and Xq11-23 (Saramaki & 
Visakorpi 2007, Cheng et al. 2012). Alterations in chromosome 8 are quite common 
(both gains and losses) and they have been known for almost two decades already 
(Matsuyama et al. 1994, Van Den Berg et al. 1995). With chromosome 8 alterations it 
is interesting that the prevalence of these alterations comes much more common along 
the progression of prostate cancer. When the stage of the prostate cancer increases the 
chromosome alterations of chromosome 8 follow and in the hormone refractory prostate 
cancer there is chromosome 8p deletion and 8q gain simultaneously in 60% of cases 
(El Gammal et al. 2010). There are some known genes associated with cancer in areas 
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of deletion and gain in chromosome 8. Notable are at least NKx3.1 which is lost from 
8p21.2 and MYC which is gained in 8q24.21 (Boyd et al. 2012). 
 
2.3.2 Gene fusions 
 
Important factors in prostate factor which are also important factors of this master thesis 
are gene fusions. A fusion gene is a hybrid gene formed from two previously separate 
genes (Mitelman et al. 2007). Good known example of these fusions in other cancers is 
BCR-ABL1 gene fusion in leukemia (Rana et al. 2013). This fusion is good example 
of long known fusion which has high clinical relevance in treatment of decease (Rana 
et al. 2013). In prostate cancer there is recurrent chromosomal translocation between 
the ETS transcription factor family of genes and the TMPRSS2 gene. As consequence 
of this gene fusion, the expression of ETS genes is now controlled by TMPRSS2 
promoter (Boyd et al. 2012). Especially important TMPRSS2:ETS fusion is the fusion 
between ERG and TMPRSS2 genes. This is not only the most recurrent TMPRSS2:ETS 
but there is also evidence that there is an association between the presence of this fusion 
and the outcome of the cancer. There is evidence that TMPRSS2-ERG fusion is early or 
even initial fusion in some prostate cancers. This fusion is detected less frequently in 
PINs than in tumor lesions but it is detected frequently in PINs which lead to fusion-
positive tumors (Boyd et al. 2012). The mechanism behind this gene fusion is not fully 
understood, however the proximity between TMPRSS2 and ERG can be induced in both 
malignant and nonmalignant prostate cells following androgen treatment, suggesting an 
early role in prostate carcinogenesis (Boyd et al. 2012). After the suggestion that fusion 
induction results from gene colocalization and double-strand break (DSB) generation it 
was found that androgen signaling promotes corecruitment of AR and DNA 
topoisomerase 2-β (TOP2Β) to sites of TMPRSS2-ERG genomic breakpoints, this in 
turns can trigger  a recombigenic TOP2B mediated DSBs (Haffner et al. 2010, Boyd et 
al. 2012).  
 
There are also other possible fusion partners detected for the TMPRSS2 gene. ETS 
genes—such as ETV1, ETV4, ETV5, and FLI1—have been identified as TMPRSS2 3' 
fusion gene partners. In addition, a number of 5' partners—including SLC45A3, ERVK-
24 (also known as HERVK_22q11.3), HNRPA2B1, C150RF21, and NDRG1—have 
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been identified in ETS gene fusions so not only the TMPRSS2 provides promoter 
regions for genes related prostate cancer (Boyd et al. 2012). 
 
Because TMPRSS2 is important factor in my master’s thesis I will talk about it little bit 
more. TMPRSS2 is androgen regulated gene and it is preferentially expressed in 
prostate. TMPRSS2 is normally expressed exclusively in the normal basal cell 
population (Lin et al. 1999, Gasi Tandefelt et al. 2014). In androgen sensitivity cell line 
LNCaP addition of androgen results in increased TMPRSS2 expression which 
demonstrates the fact that TMPRSS2 is androgen regulated. Also when the expression 
of TMPRSS2 is examined from xenografts that recapitulate the androgen-dependent and 
subsequent androgen-independent characteristics of human prostate cancer growth, it 
is seen that TMPRSS2 is expressed also in cells which have reached the androgen-
independent state. This indicates possible dysregulation of TMPRSS2 control (Lin et al. 
1999). TMPRSS2 is located on chromosomal band 21q22 common fusion companion 
ERG is also in the same band and distance between them is only 3 Mb. Proximity of 
these genes makes sense because they are so common fusion partners (Gasi Tandefelt 
et al. 2014). However SKIL is located to different chromosome 3q26 (Deheuninck & 
Luo 2009). This might sound problematic in terms of fusion to happen but there are 
many other cases such as ERG fusion to SLC45A3 which happen despite the fact that 
they are not in genomic proximity of each other (Gasi Tandefelt et al. 2014). 
 
There are also gene fusions which don’t include either ERG or TMPRSS2. For example 
DOT1L-HES6 fusion is showed to drive prostate cancer growth in androgen 
independent manner (Annala et al. 2014). In this study it was found that there was an 
interchromosomal rearrangement that fused intron 9 of DOT1L with a position 4 kb 
upstream of HES6, resulting in HES6 overexpression, which however wasn’t showed 
on protein level (Annala et al. 2014). 
 
2.3.3 Oncogenes 
 
Genes with ability to contribute cancer with gain-of-function mutations are called 
proto-oncogenes. As name suggests proto-oncogenes can become oncogenes. This 
happens typically through point-mutations, amplifications or rearrangements. Typically 
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oncogenes have great impact on signaling pathways. There are oncogenes that are 
important factors in various different cancers and some that are specific only in some 
types of cancers.  
 
When talking about cancer specific proto-oncogenes there is pretty good example in 
prostate cancer: AR. AR codes for androgen receptor which is a nuclear receptor that 
has many functions in human development and physiology. Unfortunately AR is also 
involved strongly in prostate cancer where it plays role usually after the hormone 
therapy (Li & Al-Azzawi 2009). The transition from proto-oncogene to oncogene 
usually happens during the prostate cancer progression (Visakorpi et al. 1995, Han et 
al. 2005). AR is activated in most cases through the amplifications in the DNA. Gain-
of-function mutations are quite rare in this case (Visakorpi et al. 1995). Because growth 
of the prostate cancer is heavily dependent on androgens it seems that high levels of 
androgen receptors can help cells to sustain growth even when there is little androgen 
present (Visakorpi et al. 1995). Allthough AR is usually related to prostate cancer it also 
seems that it may have oncogenic role in the breast cancer (surprisingly) but this needs 
more evidence before we can be sure about it (Hickey et al. 2012).    
 
2.3.4 Tumor suppressor genes 
 
There are genes which in case of loss-of-function mutation can drive cells towards the 
development of cancer. These cells are called tumor suppressor genes. There are several 
ways which can cause the loss-of-function mutations. Typical ways are by 
chromosomal deletions, point mutations or by epigenetic mechanisms. Good thing 
however is the fact that usually there needs to be alterations in both alleles of the gene 
before any development towards cancer happens (Alberts 2008). There are some typical 
features which are common with different suppressor genes. Typical functions that are 
regulated by tumor suppressor genes are the detection and repair of DNA damage, 
protein ubiquitination and degradation and cell cycle checkpoint responses (Sherr 
2004).  
 
Common loss-of-function tumor suppressor gene in prostate cancer and in many other 
cancers is TP53 which codes p53 protein. Normally TP53 is activated in response to 
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cellular stress such as DNA damage, and when activated p53 gets phosphorylated and 
it acts as a transcription factor. The activation of the p53 pathway can result in cell cycle 
arrest, cell senescence and apoptosis (Levine 2011). Docetaxel is a drug which is 
commonly used in the treatment of the castration resistant prostate cancer. In recent 
study it was found out that this drug induces the phosphorylation of p53. In accordance 
with this study the docetaxel sensitivity of prostate cancer is gratly affected by the 
mutational status of p53 (Liu et al. 2013). Very well-known example of effects of 
mutation in TP53 is Li-Fraumeni syndrome (Kamihara et al. 2014).  
 
PTEN is another well-known tumor suppressor gene. PTEN is known to be inactivated 
in many different cancers such as glioma, melanoma and carcinoma of the 
endometrium, kidney, breast, lung, upper respiratory track and prostate cancers (Li et 
al. 1997, Pourmand et al. 2007). PTEN, which is located in 10q23, codes for dual-
specificity phosphatase and is known to act as a part of the PI3K-PTEN-AKT signaling 
pathway. This is a pathway which, as in many other cases with pathways associated 
with cancer, is known to regulate many important cellular processes such as apoptosis, 
cell metabolism, cell proliferation and cell growth (Pourmand et al. 2007). PTEN is 
normally a negative regulatory factor of PI3K–AKT pathway, so the loss of PTEN 
function promotes ell growth, survival and proliferation (de Muga et al. 2010). 
Inactivation of PTEN is frequent event also in prostate cancer progression and the lack 
of PTEN expression is known to correlate with advanced pathological state and with a 
high Gleason score (de Muga et al. 2010). There is frequently PTEN mutation in 
metastatic prostate cancer but how frequent it is not clear and varies between different 
studies in range from 20 to 60% (Pourmand et al. 2007, de Muga et al. 2010).       
 
2.3.5 Epigenetics  
 
Word “epigenetics” means changes in DNA which don’t alter the sequence of DNA. 
They induce conformational changes in the DNA double helix and with that they 
modify the access of transcription factors to the DNA. Epigenome comprises all the 
changes in DNA methylation, histone modification, nucleosome remodeling and RNA-
associated silencing. In cancer there is often if not always epigenetic changes in addition 
to genetic changes. In the carcinogenesis of prostate cancer somatic epigenetic 
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alterations appear earlier and more frequently than genetic sequence changes. Already 
there is multiple genes which are known to be silenced in prostate cancer. These genes 
provide new possible biomarkers and can help us to understand prostate cancer 
mechanisms better (Albany et al. 2011).  
 
DNA methylation changes are common in prostate cancer. DNA methylation means 
covalent chemical modification of DNA by adding the methyl (-CH3) group at the 
carbon-5 position of the cytosine ring. Usually promoters are unmethylated however in 
prostate cancer there is often hypermethylation of promoters (Albany et al. 2011). This 
modification can silence many classical tumor suppressor genes involved things like 
hormone signaling, DNA repair, cell adhesion, cell-cycle control, and apoptosis 
(Maruyama et al. 2002, Yegnasubramanian et al. 2004, Jeronimo et al. 2004). 
Interestingly tumor suppressor genes such as PTEN, RB1 and TP53 that are frequently 
altered in many other common cancers are usually not hypermethylated in prostate 
cancer (Albany et al. 2011). Another common methylation change in prostate cancer is 
CpG hypermethylation of GSPT1. This methylation is even used as biomarker for 
prostate cancer (Wright & Lange 2007).  
 
AR which is the most studied transcriptional activator in prostate cancer seems also to 
be controlled at least in some degree by the epigenetic mechanisms. When comparing 
castrate resistance prostate cancer (CRPC) to untreated tissue it is found out that 
hypermethylation of AR is more frequent in CRPC (28%) than in untreated tissue 
(10%). This suggests that hypermethylation may have important roles in regulation of 
AR (Nakayama et al. 2000). Also histone acetylation is known to play important role 
in the regulation of AR-pathway (Nakayama et al. 2000). There has also been studies 
where the main interested has been in possible reversibility of castrate resistance in PC 
cell lines. This was done by using the hypomethylating agent azacitidine in combination 
with the antiandrogen bicalutamide. Results showed that this method worked with PC-
3 cells but failed to work in 22RV1 cells. Also in another study hypomethylation was 
studied as a therapeutic option to counteract resistance to androgen deprivation in both 
AR positive and negative cell lines. However other models needs to be used to get more 
reliable results in this matter (Gravina et al. 2008, Gravina et al. 2010, Chen et al. 2010, 
Alva et al. 2011).  
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In addition to hypermethylation there is of course chance of hypomethylation of DNA. 
Indeed there are several malignancies including prostate cancer where hypomethylation 
can be found (Albany et al. 2011). It seems that there is usually first hypermethylation 
and only after that hypomethylation can be detected in DNA. This means that usually 
hypomethylation can be detected only from higher stage cancers and it seems to occur 
heterogeneously during prostate cancer progression and metastatic dissemination 
(Nelson et al. 2007). There are several mechanisms which are hypothesized to 
contribute the oncogenesis of hypomethylation. Suggested mechanisms are at least 
activation on oncogenes, activation of latent retrotransposons and contribution to 
genomic instability (Kulis & Esteller 2010).  
 
Also it seems that histone modification plays important role in prostate cancer 
tumorigenesis. The global level changes in individual’s histone modifications are 
showed to be predictive in clinical outcome of prostate cancer independently of other 
features such as tumor stage, preoperative prostate-specific antigen levels, and capsule 
invasion (Seligson et al. 2005). There are two global methylations of H3K4 and histone 
H3 lysine 18 acetylation (H3K18Ac) which are independent predictor of recurrence in 
low-grade prostate cancer (Seligson et al. 2005, Zhou et al. 2010).      
 
2.4 TGF-β signaling         
 
Transforming growth factor β is a ubiquitous cytokine that has effects in various 
different biological processes also the functions of TGF-β signaling are important in 
my master thesis. In many epithelial cells TGF-β is negative growth factor and loss of 
this growth inhibition is a hallmark of many different cancer types (Liu et al. 2001). 
TGF-β causes cells to accumulate in mid-to-late G1 phase of the cell cycle by blocking 
the transition from G1 to S. TGF-β binds to type II receptor on the cell surface and this 
leads to the recruiting of type I receptors. Both of these receptors are ser./thr. kinases. 
This means that type II receptors phosphorylate the type I receptors and then type I 
receptors in turn phosphorylate its intracellular substrates, which are Smad2 and 
Smad3. After this the two proteins can bind with Smad4 and form a complex. This 
complex can then move to nucleus and functionally collaborate with different 
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transcription factors (Liu et al. 2001). Cell cycle progression through the G1/S 
transition requires activation of the cyclin E/cdk2 complex (Liu et al. 2001).  
 
There are two major pathways which Smad complex can use to inhibit the cyclin E/cdk2 
complex which activity is needed cells to get past the G1 restriction point. First it can 
activate transcription of two inhibitors of cyclin-dependent protein kinases, p21Cip1 and 
p15INK4B (Liu et al. 2001). In this quite complicated mechanism increase in levels of 
p15INK4B cause it to displace p27Kip1 from the complex of cyclin D/cdk4/6, then in turn 
p27Kip1 is free to bind cyclin E/cdk2 complex. Binding of p27Kip1 inactivates the kinase 
activity of cyclin E/cdk2 complex and this leads to cell cycle arrest. Smad complex can 
also repress the transcription of c-myc. Myc is able to induce the transcription of cdc25a 
which is phosphatase that causes the dephosphorylation cdk2. This is necessary step for 
cdk2 kinase activation. Many different mutations have been found which can disturb 
the normal activity of TGF-β signal cascade inside of the cell. For example mutation in 
Smad4 which causes its inactivation can be found from up to 50% of all pancreatic 
tumors. Mutations in Smad2 are found in colorectal carcinomas and alterations of type 
II receptor occur in 90% of colon cancer cells with microsatellite instability (Liu et al. 
2001). Also crosstalk between different signaling pathways can lead to TGF-β signaling 
inhibition. One way this to happen overexpression of the proto-oncogenes ski, sno or 
evi-1 (Liu et al. 2001). 
 
2.5 Role of SKIL in cancer progression 
 
Gene ski was originally discovered in the avian Sloan–Kettering viruses that formed 
during the passaging of a transformation-defective avian leukosis virus. This is called 
v-ski which is found to arise from cellular gene c-ski. Cellular homologs of c-ski has 
been found from many species: at least human, mouse, chicken and zebra fish homologs 
are known to exist (Liu et al. 2001). Normal function of ski seems to be related to 
differentiation of cells. This was found ski knock-out models were made with mice and 
there were multiple defects in the central nervous system and in skeletal muscle 
development. Another gene SKIL (also known as sno, ski-related novel gene) was later 
found when probing human cDNA libraries using v-ski. There are several isoforms of 
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this gene in human: snoA, snoN (SKIL), snoN2 and snoI (Pearson-White 1993, Pearson-
White & Crittenden 1997).  
 
Several things support the oncogenic nature of SKIL. First it seems that level of SnoN, 
protein encoded from SKIL are elevated in many different cancers such as esophageal 
squamous cell carcinoma (Imoto et al. 2001a, Fukuchi et al. 2004), melanoma (Chen et 
al. 2003, Reed et al. 2005), estrogen receptor-positive breast carcinoma (Zhang et al. 
2003), colorectal carcinoma (Buess et al. 2004) and leukemia (Pearson-White et al. 
1995, Ritter et al. 2006). In addition to that as earlier said SKIL is located in 3q26. This 
locus is frequently amplified in many tumors, including cancers of the lung (Racz et al. 
1999, Sugita et al. 2000), esophagus (Imoto et al. 2001b), head and neck (Singh et al. 
2001, Lin et al. 2005), cervix (Sugita et al. 2000, Hopman et al. 2006), ovary (Sugita 
et al. 2000, Nanjundan et al. 2007) and prostate (Jung et al. 2006). It is important to 
note however that this locus has also other genes which are known to be oncogenes so 
the amplification of this locus alone is not sufficient proof for SKIL to be oncogene. 
Stronger evidences come from the studies where siRNAs are used to decrease the 
expression of SnoN in human lung or breast cancers and this inhibits the tumor growth 
both in vitro and in vivo (Zhu et al. 2007). Also the down regulation of SKIL in 
pancreatic cancer cells reduces the tumor growth (Heider et al. 2007). Interestingly 
siRNA treatment targeting SKIL in lung and breast cancer has no effect on the 
transforming activity of these cells. This may mean that tumor-promoting activity of 
SnoN is restricted to certain type of cancers only (Zhu et al. 2007, Deheuninck & Luo 
2009).       
 
When ski oncogene was discovered it took many years to find out the molecular 
mechanism behind this molecule. It seemed that ski had many effects on transcription 
but it also seemed that it couldn’t bind the DNA. Then simultaneously several groups 
found out that ski can directly bind to Smad3/4 complex. This means that cells can’t 
respond normally to the TGF-β stimulation. More precise studies showed that it is 
Smad3 which can bind the SnoN protein in human. It was also shown that this binding 
of SnoN to Smad3 happens only after TGF-β stimulation in several different cultured 
cells (Liu et al. 2001). Previously there had been attempts to identify DNA binding site 
for Ski and by using the in vitro selection protocol (Nicol & Stavnezer 1998). They 
found that DNA binding site for Ski is GTCTAGAC. Later another group found that 
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the binding site for Smad3 and Smad4 is exactly the same GTCTAGAC. This lead to 
hypothesize that Ski can only bind to DNA indirectly when bound to Smad3 and indeed 
this was showed to be true later. Interestingly this Smad3-Ski/SnoN complex doesn’t 
activate the Smad-responsive genes but represses them (Nicol & Stavnezer 1998, Liu 
et al. 2001). This explains in which way the overexpression of Ski/SnoN antagonizes 
the normal effects of TGF-β stimulation. Also the overexpression of Smad3 and Smad4 
can reverse the effects of Ski/SnoN overexpression. This suggests that there is 
antagonistic relationship between the Smad3/4 and Ski/SnoN (Liu et al. 2001).  
 
Cells can normally control the levels of Ski and SnoN. This also happens through the 
TGF-β stimulation. Cells treated with TGF-β show decreased levels of Ski and even 
more decreased levels of SnoN. However it is possible to inhibit this loss of Ski and 
SnoN. This can be done by pretreating cells with MG132, which is proteasome inhibitor 
that can block the protein degradation via a proteasome-mediated degradation pathway. 
This indicates that TGF-β signaling pathway can somehow cause proteasome-mediated 
degradation of Ski and Sno (Sun et al. 1999). Interestingly there is also study which 
shows that with Hep3B cells short exposure of TGF-β indeed decreases the levels of 
SnoN but longer exposure lead to clearly increased levels of SnoN. It was showed that 
this is due to increased mRNA levels of SnoN upon 2h treatment with TGF-β. Because 
of these results it is suggested that SnoN is a nuclear corepressor for Smad4 to maintain 
TGF-b responsive gene expression at a basal level (Stroschein et al. 1999). So when 
the Smad proteins are phosphorylated it triggers the nuclear translocation which then 
can trigger the SMad3-dependent degradation of SnoN thus allowing activation of 
TGF-β pathway downstream genes. After this the transcriptional activation of SnoN 
steadily starts to increase the steady state levels of SnoN and this eventually leads to 
inhibition of TGF-β pathway. Same study also found out that more stable mutant of 
SnoN can more effectively turn of the transcriptional activation of TGF-β responsive 
genes. This result is also consistent with earlier findings (Stroschein et al. 1999, Liu et 
al. 2001).  
 
All though the TGF-β inhibition seems to be the most important pathway connected to 
oncogene feature of SnoN and Ski, there is also other cellular targets for these proteins. 
Ski can directly bind to N-CoR/SMRT and mSin3A to form a complex with HDAC. 
This means that when Ski is bind to Smad2/3/4 complex which is activated by TGF-β 
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signaling it can same time bind to N-CoR/SMRT which in turn can recruit HDAC. 
HDAC can promote histone deacetylation, resulting in shutting down the transcription 
(Nomura et al. 1999, Liu et al. 2001). Deletion of binding site of N-CoR clearly 
decreases the inhibition activity of Ski which is consistent with other results (Nomura 
et al. 1999).  
 
2.6 Previous results from SKIL studies  
 
Starting point for this study was the identification of novel TMPRSS2-SKIL gene fusion 
from fresh frozen tissues acquired from the Tampere University Hospital (Tampere, 
Finland). There were tissue from 12 benign prostatic hyperplasias (BPH), 28 untreated 
prostate cancers (PC), and 13 castration resistant prostate cancers (CRPC) in the cohort. 
We then screened 76 additional tumors and 22 LuCaP xenografts with qRT-PCR, and 
identified SKIL overexpression in one xenograft and one clinical sample. These samples 
had different fusion partners MIPEP for the clinical and SLC45A3 for the LuCaP-77. 
Also none of the coding sequences disrupted the protein coding sequence of SKIL, 
suggesting that SKIL is still functional. We also found that inhibition of SKIL with 
siRNA in PC-3 and LNCaP cell lines decreased the growth rates of the cells and 
increased the invasion of cells with PC-3 cells.  
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3. AIMS OF THE RESEARCH 
 
The goal of this Master’s thesis was to clarify the functional role of the SKIL 
overexpression in prostate cancer. There are already several studies which suggests that 
SKIL is potential oncogene in several cancers. Previous studies performed with SKIL 
showed that SKIL might be important factor in some subtypes of prostate cancer. Aims 
of this study were: 
 
1) Construction of prostate cancer cell line steadily overexpressing SKIL. 
2) Analyzing the effects of overexpression of SKIL in prostate cancer cells.   
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4. MATERIAL AND METHODS 
 
4.1 Subcloning of SKIL 
 
Starting materials for the subcloning of SKIL were pCMV6-XL4/5/6 vector (Origene) 
with full SKIL gene and empty pcDNA3.1(+) vector (Invitrogen). Enzymes used with 
subcloning were EcoR1 and NotI (Thermo scientific). Restriction reactions with both 
plasmids were performed as double digestion in Buffer O (Thermo Scientific) at 37 °C 
for 4,5 hours after which inactivation was performed at 80 °C for 20 minutes. After 
restriction 1,5% agarose gel was used to separate the SKIL insert and linearized 
pCMV6-XL4/5/6 plasmid. The SKIL insert was cut out from the gel and restricted using 
the QIAquick Gel Extraction Kit (Qiagen). The linearized pcDNA3.1(+) vector was 
purified using QIAquick PCR Purification Kit (Qiagen). After purifications ligation 
reaction was performed using T4-DNA ligase T4-buffer (Fermentas). Reaction was 
performed at room temperature for 10 minutes and inactivated at 70 °C for 5 minutes.  
 
Constructs were then transformed into One Shot® chemically competent TOP10 e. coli 
cells. Then transformed e. coli cells were cultured overnight at 37 °C on LB plates 
containing 50 µl/ml of ampicillin. Multiple colonies were taken and cultured in 200 µl 
of LB medium for 4 hours. Colony PCR was performed as described below on all 
recultured colonies with SKIL specific primers. Possible SKIL positive colonies were 
then cultured in 4 ml of LB medium containing 50 µl/ml of ampicillin. Next day plasmid 
DNA was extracted by using the GenElute™ Plasmid Miniprep Kit (Sigma-Aldrich). 
This DNA was then sequenced as described below. 
 
4.1.1 Colony PCR 
 
Following components per each reaction was pipetted: 20 µl PCR-water, 4 µl 5x 
Phusion GC buffer (Thermo Scientific), 0,4 µl 10 mM dNTPs (Thermo Scientific), 0,5 
µl both 50 µM forward and reverse primer, 0,5 µl of Phusion DNA polymerase (Thermo 
Scientific) and 2 µl of LB medium with bacteria. Samples were then moved to PCR-
machine and following program was ran: initial denaturation 98 °C for 5 minutes, 
denaturation 98 °C for 10 seconds, annealing 65 °C for 30 seconds, extension 72 °C for 
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30 seconds then 34 times to denaturation step then final extension at 72 °C for 10 
minutes.         
 
4.1.2 DNA sequencing 
 
Sequencing of plasmid DNA was performed by using the Sanger’s method using 
BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems) and ABI-3130xl 
genetic analyzer (Applied Biosystems). Prior to sequencing DNA was amplified by 
using the Bio-Rad C1000TM Thermal Cycler (Bio-Rad). In each sequencing reaction 
1 µl of BigDye Terminator reaction mix (Applied Biosystems), 1,5 µl of 5x sequencing 
buffer, 1 µl of 5 µM primer and 100-300 ng of DNA was added. The total volume of 
all reactions were adjusted to 10 µl by using sterile, deionized water. Primers which 
were used to sequencing are shown in the table 1. Reactions were denatured at 95 °C 
for 3 minutes, followed by 45 s at 95 °C, 10 s at 50 °C and 4 min at 60 °C followed by 
25 cycles of 15 s at 98 °C, 10 s at 50 °C and 4 min at 60 °C. After amplification DNA 
was precipitated by adding 25 µl absolute ethanol and 1 µl of 3 M sodium acetate (pH 
5.2). Reactions were incubated 15 minutes at room temperature. Then reactions were 
centrifuged at 2000 g for 45 minutes, followed by immediately centrifugation at 700 g 
for 1 min upside-down. This was done to discard the supernatant perfectly. DNA was 
washed with 125 µl of 70% ethanol and the pelleted again with centrifugation at 2000 
g for 15 minutes. Ethanol was removed again with 700 g centrifugation for 1 min 
upside-down. DNA pellets were then resuspended to 12,5 µl of Hi-DiTM formamide 
(Applied Biosystems). DNA was denatured by incubating at 95 °C for 3 minutes. 
Samples were then briefly centrifuged and sequenced with ABI-3130xl genetic 
analyzer (Applied Biosystems).  
 
4.3 Cell lines 
 
Cell lines used in this study are PC-3, DU-145, EP156T and RWPE-1. These were 
obtained from the American Type Culture Collection (ATCC). All the cells were 
cultured at 37 °C and 5% CO2 all the time. All the cell cultures were subcultured every 
three to four days if not mentioned differently. The basal media for PC-3 cells was 
Ham’s F12 with 10% fetal bovine serum and 2 mM L-glutamine. For DU-145 cells 
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basal media was Eagle's Minimum Essential Medium with 10% fetal bovine serum and 
2 mM L-glutamine. For EP156T cells basal media was Keratinocyte Serum Free 
Medium with 0.05 mg/ml BPE, 5 ng/ml EGF and 1nM DHT. For RWPE-1 cells basal 
media was Keratinocyte Serum Free Medium with 0.05 mg/ml bovine pituitary extract 
(BPE) and 5 ng/ml epidermal growth factor (EGF). Basal media and fetal bovine serum 
were purchased from Lonza. 
  
4.3.1 Transient transfection  
 
Transfection of prostate cancer cells with SKIL construct were performed using the 
jetPRIME® transfection reagent (Polyplus-transfection). 100 000 cells were seeded on 
the 6-well plate and then incubated 24 hours at 37 °C and 5% CO2. Transfections were 
performed according to manufacturer’s instructions. All the control cells were 
transfected with the expression vectors lacking the SKIL insert. RNA and proteins were 
extracted from the cells within 24 hours.  
 
4.3.2 Stable transfection 
 
Transfection of prostate cancer cells leading to stable transfection were performed using 
the jetPRIME® transfection reagent (Polyplus-transfection).  250 000 cells were seeded 
to T75 cell culture flasks (Sigma Aldrich) and then incubated 24 hours at 37 °C and 5% 
CO2. Again transfections were performed according to manufacturer’s instructions. All 
the control cells were transfected with the expression vectors lacking the SKIL insert. 
24 hours from the transfection medium (described under the “cell lines”) of the cells 
was changed to that containing 150 µg/ml geneticin®  selective antibiotic (also known 
as G418 or G-418). After this cells were let to grow in the medium for about 4 weeks. 
Medium was changed every three days and cells were frequently monitored. During 
this time most of the cells first died because of geneticin but after about three weeks 
cells started slowly grow again. After cells started growing normally amount of 
geneticin in medium was reduced to 100 µg/ml just to restrain the vectors in the cells.  
 
After this DU145 cells with stable SKIL insert were used to create single-cell clones. 
First cells were detached from flask as described under the “cell lines”. Mixed 
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population of cells was diluted 30 cells/ml to extablish monoclonal lines. Dilution was 
seeded to 96-well plate (total volume of 500 µl per well) and put to incubator. Again 
medium was carefully changed every three days and cells were frequently monitored. 
After cells started to grow normally again they were subcultured to bigger T75 flasks. 
With this technique we got some wells were all the cells were originally from one cell 
only thus they are all clones. 
 
4.4 RNA extraction and RT-qPCR 
 
RNA was extracted from cells by using the TRI Reagent® (Sigma). This RNA 
extraction was performed according the manufacturer’s instructions. Before the 
extraction cells were seeded on 6-well plate containing 50 000 cells/plate. For real time 
quantitative PCR (RT-qPCR) RNA was first reverse transcribed by using the Maxima 
Reverse Transcriptase (Thermo Scientific) and random hexamer primers (Thermo 
Scientific). First 1 µg of RNA and 200 ng of random hexamer primers are adjusted to 
12,5 µl using sterile, deionized water. Reactions are then incubated at 65 °C for 5 
minutes. Next master mix with 4 µl of Maxima 5x buffer (Thermo Scientific), 2 µl of 
10mM dNTP mix (Thermo Scientific), 0,5 µl of RNase inhibitor (Thermo Scientific) 
and 1 µl of Maxima Reverse Transcriptase enzyme (Reverse Transcriptase). After that 
25 °C for 10 min, 50 °C for 30 min and 85 °C for 5 min. Standard curves were prepared 
from the RNA extracted from the non-transfected PC-3 cells by using the 5-fold dilution 
series. All expression values were normalized by using the housekeeping gene TBP 
(TATA binding protein). Sterile water was used as a negative control. The Real time 
quantitive reverse transcription PCR (RT-qPCR) itself was carried out by using the Bio-
Rad CFX96™ Real-Time PCR Detection System (Bio-Rad) with MaximaTM SYBR 
Green/ROX qPCR Master Mix (Fermentas). Reactions were prepared by using the 
manufacturer’s instructions and reaction conditions were optimized for primers used. 
Primers which were used are shown in table 1. RT-qPCR results were analyzed by using 
the CFX Manager Software.       
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4.5 Protein extraction and measurement of concentration 
 
Cells were seeded either on 6-well plate or on the T75 flasks. Proteins were harvested 
when cells were75-85 % confluent. Cells were first washed three times with the ice cold 
PBS (10 ml for the T75 flask and 2 ml for 6-well plate) while on ice. Then small amount 
of PBS (750 µl for the T75 flask and 500 µl for the 6-well plate). Cells were then 
detached by using the cell scraper. PBS with the cells was then harvested. This was 
repeated to ensure that all the cells are collected. Cell were centrifuged at 200 g for 5 
minutes at 4 °C. Supernatant was discarded. Cells were then resuspended to 50 µl of 
hypotonic buffer. Hypotonic Buffer has 10 mM Hepes (pH 7,9), 1,5 mM MgCl2, 10 
mM KCl, 0,2 mM PMSF, 0,5 mM DTT and 40 µl of complete protease inhibitor 
(Roche)/1 ml. Cells were incubated on ice for 10 minutes and centrifuged at 2000 g for 
15 minutes at 4 °C. Supernatant containing the proteins was collected.  
 
Protein concentration was measured by using the reagents from the Bio-Rad. First 
standard curve was prepared by using the 1 mg/ml BSA, water and Bradford reagent 
(Bio-Rad). 2-fold dilutions were used. Protein samples were prepared to 1:100 and 1:50 
dilutions using the water and Bradford reagent (Bio-Rad). All the dilutions were done 
as the triplicates on the 96-well plate with flat bottoms. After pipetting plate was shaken 
and incubated at RT for 15 minutes. Protein concentration was measured using the 
EnVision® 2104 multilabel reader.  
 
4.6 Western blotting 
 
For western blotting proteins extracted were first prepared in the following way. About 
20 µg of protein was added to 9 µl of 3xSS and 1 µl of 1,25 M DTT. Total volume was 
adjusted to 30 µl. Samples were denatured at 99 °C for 5 minute and chilled on ice. 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
separate the proteins according the size. SDS-PAGE is made in a way that first there is 
lower gel which is pipetted first followed by less concentrated upper gel. Lower gel was 
prepared in following way: 2,95 ml of water, 2,5 ml of 30% acrylamide mix (BIO-
RAD), 1,9 ml of 1,5 M Tris (pH8,8), 0,075 ml of 10% SDS, 0,075 ml of 10% APS and 
0,003 ml of TEMED (Sigma Aldrich). Upper gel was prepared in following way: 1,7 
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ml of water, 0,415 ml of 30% acrylamide mix (BIO-RAD), 0,315 ml of 1,5 M Tris 
(pH8,8), 0,025 ml of 10% SDS, 0,025 ml of 10% APS and 0,0025 ml of TEMED 
(Sigma Aldrich). Gel was then loaded with samples and molecular markers. Markers 
used were PageRuler™ Prestained Protein LadderPlus (Fermentas) and ColorPlus™ 
Prestained Protein Ladder, Broad Range (New England Biolabs). Gel was run first 100 
V for 15 minutes and then 150 V for 1 hour.   
 
Western blotting was performed using Trans-Blot® SD Semi-Dry Transfer Cell system 
(BIO-RAD). First nitrocellulose membrane or polyvinylidene difluoride (PVDF) 
membrane was prepared. Nitrocellulose membrane was dipped to methanol and straight 
to the water. Membrane was then moved to transferring buffer (25 mM Tris, 192 mM 
glycine, 10% methanol). Also six Whatman filters (Sigma Aldrich) were incubated in 
the transferring buffer. PVDF membrane was prepared in the same way expect it was 
not dipped to the methanol first. Blotting machine was assembled in the way that first 
it was slightly moistened with transferring buffer. Three Whatman filters were laid and 
on the top of them membrane, gel and three more filters, respectively. Blotting was 
performed in 1 hour using 12 V and 80 mA. After blotting membrane was checked to 
see if protein size markers were transferred to membrane. After blotting membranes 
were blocked in 3% BSA/0,1% Tween/PBS for 1 hour at RT on shaker. Membranes 
where then transferred to primary antibody which was 5% BSA/0,1% Tween/0,1% 
NaN3 and 1:1000 SnoN antibody (Cell Signaling Technology) in BSA. Membranes 
were then incubated at 4 °C over night in shaker. Membranes were washed three times 
first with 0,5% Tween in BSA then 0,1% Tween in BSA and finally 0,05% Tween in 
BSA. Membranes were then transferred to secondary antibody, which was 0,1% Tween 
and 1:5000 anti-rabbit (P0217, Dako) in BSA. Membranes were incubated for 1 hour 
at RT in shaker. Membranes were washed again as before. After final wash the 
membranes were rinsed with BSA and moved to transparent film. Then mixture (1:4) 
of Immunocruz Western Blotting Luminol Reagent SC-2018 (Santa Cruz) and 
SuperSignal® West Femto Maximum Sensitivity Substrate (Thermo Scientific) was 
added to the top of the membrane. Membranes were incubated for 30 seconds. After 
this the membrane was moved to Kodak cassette (Kodak) which can be sealed in the 
way that no light can enter. Next steps were performed at the dark room. There X-ray 
film was exposed to the membrane. Exposure time was varied between 5 seconds and 
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5 minutes to find the optimal result. After exposure X-ray films were developed by 
using the CP1000 table top film processor (Agfa).  
 
4.7 Growth curves 
 
Growth curves were made out of DU145, EP156T and RWPE-1 cell lines. Both stabile 
and transient transfections were used in growth curves. Growth curves were performed 
using the 24-well plates. First cells were removed from the bottom of the flask as with 
the cell splitting. Then cells were counted using the MoxiZ (Orflo). Then 20 000 cells 
per well were seeded to each well. Cells were seeded as triplicates. Then cell growth 
was quantified by using the light microscopy every day after seeding. Pictures were 
taken using the Olympus IX71 microscope and using Surveyor microscope software 
user interference. Pictures were taken as long as the cells didn’t occupied the whole 
growth area. This usually takes between 4 to 6 days. 
 
4.8 Matrigel invasion assay 
 
Matrigel invasion assays were performed with cells using BD BioCoat Matrigel 
Invasion Chambers (BD Biosciences). 24-well plate (BD Falcon TC Companion Tissue 
Culture Plates). All the samples and controls were prepared as triplicates. Chambers 
were first removed from the -20 °C and allowed to come to room temperature. Then 0,5 
ml of Eagle’s Minimum Essential Medium (EMEM, Lonza) was added to interior of 
inserts and to bottom of the wells. This was allowed to rehydrate for 2 hours at 37 °C 
and 5% CO2. All the medium was carefully removed. For RWPE-1 cells media with no 
BPE and EGF was prepared. Then concentration of cells in that media was adjusted to 
50 000 cells/ml. 0,5 ml of this medium was added to the interior of inserts. 0,75 ml of 
normal RWPE-1 media was added to the bottom of the wells. Inserts were carefully 
transferred to the wells to avoid any air bubbles between bottom of the insert and media 
in the well. Chambers were incubated for 24 hours at 37 °C and 5% CO2. Medium was 
removed from the insert and after that non-invaded cells were removed by scrubbing. 
This was performed in the way that cotton tipped swab was inserted into insert and it 
was moved there with gentle but firm pressure. This was repeated with a second swab 
moistened with medium.  
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After this invasive cells were stained. Inserts were first incubated in methanol for 2 
minutes and then in 1% toluidine blue in 1% borax for 2 minutes. After this chambers 
were rinsed twice with plenty of distilled water. Inserts were let to air dry. Membrane 
was removed from the insert with sharp scalpel and membranes were placed to the 
microscope slide with drop of immersion oil. Another drop was added and cover slip 
was placed to the top with gentle pressure to remove the air bubbles.        
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5. RESULTS 
 
5.1 Subcloning of SKIL 
 
We failed to subclone SKIL into empty pcDNA3.1(+) vector (Invitrogen). We got very 
few colonies and when those were sequenced they were all negative. Because of this 
we decided to buy commercial plasmids pCI-Neo HA-hSnoN which is a gift from 
Robert Weinberg, Addgene plasmid #10908 (Sun et al. 1999) and universal empty, pCI-
Neo backbone pUNIV-plasmid which is a gift from Cynthia Czajkowski, Addgene 
plasmid #24705 (Venkatachalan et al. 2007). 
 
5.2 Verification of SKIL expression by RT-qPCR 
 
We used commercial plasmids pCI-Neo HA-hSnoN and pUNIV backbone from 
Addgene to overexpress SKIL in prostate cancer cells. Overexpression of SKIL mRNA 
in cell lines was verified using RT-qPCR. The expression levels of SKIL in different 
cell lines are presented in the figure 1. The results show that in RWPE-1 cells mRNA 
levels of SKIL are about three fold higher in cells transfected with SKIL vector 
compared to those transfected with empty vectors. With DU145 cell line after the 
transfection cells were used to create single cell clones either with SKIL vector or empty 
vector. Clear expression differences between different clones can be seen in the figure 
1 B. However clones with empty vector (pUNIV A1 and pUNIV B1) are among clones 
with low SKIL expression. There was also clones with clearly higher SKIL expression 
(A2, A6, B3 and B4). These clones showed about 4-10 fold higher SKIL expression 
than the ones with the empty vector. We also transfected PC-3 cells with SKIL siRNA 
to inhibit the SKIL mRNA in this cell line. We detected about three fold reduction in 
SKIL mRNA expression. These results can be seen in appendix picture 1.  
 
5.3 The effects of SKIL expression on the growth of the cell lines 
 
The effects of the SKIL expression for the growth of the cell lines was tested by using 
the RWPE-1 and DU-145 cells. Growth curves were created by growing cells on 24-
well plates and pictures were taken using the Olympus IX71 microscope and using 
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Surveyor microscope software user interference. Figure 2 A shows results for cell 
growth experiments performed by using the stable transfected RWPE-1 cells. It seems 
that there are no difference in growth rates between cell transfected with SKIL vector 
and cells transfected with empty vector. Figure 2 B shows results for cell growth 
experiments performed by using the stable transfected single cell clones of DU145 
cells. In this case there are little differences which can be seen between cells transfected 
with SKIL and cells transfected with empty vector, but the difference is not statistically 
significant (p>0.05). Also it is not the clones with SKIL overexpression but the control 
clones, which grow faster. 
 
5.4 The effects of SKIL expression on the invasiveness of cell lines 
 
Invasion efficiency of cells was tested using the matrigel invasion assay (BD 
biosciences). Cell lines used were again RWPE-1 and DU-145. In figure 3 B there is 
shown cell invasion results when using the RWPE-1 cells. From there it can be seen 
that cells overexpressing SKIL seem to have higher invasiveness than those with empty 
control vector. Difference is also statistically significant (p>0.05). 
 
Figure 3 B shows results for invasion experiment made with DU-145. Cells which 
showed the highest SKIL expression in mRNA level were chosen for this experiment. 
Results show that there are clear differences between different clones of DU-145 
transfected with SKIL vector. There are two clones with empty control vector and one 
of those (A1) shows very little invasiveness capability, but other (B1) seems to show 
as much if not more invasiveness capability than clones transfected with SKIL. 
However there is one clone (A6) which shows clearly increased invasiveness capability. 
This clone was also the only one which showed statistically significant difference 
(p<0.05).                  
 
5.5 Verification of SKIL overexpression by western blotting 
 
We wanted also know the expression levels of SKIL in protein level. This was done 
using semi-dry western blotting. Proteins derived from RWPE-1, DU-145 and PC-3 
were used in western blotting. Figure 4 shows results from each different western blot. 
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Western blot created with the RWPE-1 cells fails to show any difference between cells 
transfected with SKIL and cells transfected with empty vector. As can be seen from the 
picture antibody used is not that specific and there is lot of bands that should not be 
there. Proteins extracted from DU-145 cells also gave similar results than those with 
RWPE-1. There is lot of unspecific bands and they fail to show any real difference 
between cells transfected with SKIL and cells transfected with empty vector. PC-3 cells 
again differ from the RWPE-1 and DU-145 cells in a sense that they are not stabile but 
transient transfected. Despite from that it again seems that western blotting fails to show 
any difference between cells transfected with SKIL and cells transfected with empty 
vector and there is still many unspecific bands present. All the western blots were 
repeated by using another primary antibody (Rabbit polyclonal anti-SKIL antibody, 
TA312882, Origene) but the results were similar with the ones showed here.            
         
Table 1: List of primers used in sequencing and in RT-qPCR  
Primers used in sequencing have “SEQ” in their name.  
 
NAME OF THE PRIMER  SEQUENCE 
SKIL_SEQ1_FOR 5’-TCCTTGAAGGTAACTGGGCA-3’ 
SKIL_SEQ1_REV 5’-TCCAGGGTCAATGCAATGGT-3’ 
SKIL_SEQ2_FOR 5’-AATGGGATGGGAGATGATGGC-3’ 
SKIL_SEQ2_REV 5’-GCGACATGCTTTCTTGGGAA-3’ 
SKIL_SEQ3_FOR 5’-TTGCCACTGGGGCTTTGAAT-3’ 
SKIL_SEQ3_REV 5’-CTGTGAGCCTTCTCTGACTGT-3’ 
SKIL_SEQ4_FOR  5’-GACAGGAACGGGAAGCAAGA-3’ 
SKIL_SEQ4_REV 5’-TGCCTAGTTATCGTCATGCAG-3’ 
T7_SEQ_FOR 5-’TAATACGACTCACTATAGGG-3’ 
TBP_FOR 5’-GAATATAATCCCAAGCGGTTTG-3’ 
TBP_REV 5’-ACTTCACATCACAGCTCCCC-3’ 
SKIL_FOR 5’-AGAGGCTGAATATGCAGGACA-3’ 
SKIL_REV 5’-CCAAAGCAAGCAACAAACAA-3’ 
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Figure 1: Relative mRNA expression levels of SKIL 
A) The expression of SKIL mRNA in RWPE-1 cells stable transfected with SKIL or with empty expression vector. Error bars represent standard 
deviations of RT-qPCR replicates. P<0.05 (unpaired T-test). B) The expression of SKIL mRNA in single cell cloned DU145 cell lines with SKIL 
or with empty expression vector. Error bars represent standard deviations of RT-qPCR replicates. P<0.05 when A2, A6 or B3 is compared to 
pUNIVA1 or to pUNIVB1 (unpaired T-test).       
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Figure 2: Growth curves of RWPE-1 and DU-145 cells 
A) Growth curves of RWPE-1 cells stable transfected with SKIL and empty control vector. Error bars represent standard deviation of replicate 
wells. B) Growth curves of DU-145 cells stable transfected with SKIL and empty control vector. Error bars represent standard deviation of 
replicate wells.   
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Figure 3: Number of cells invaded in Matrigel invasion assay  
A) Number of RWPE-1 cells invaded during the Matrigel invasion assay. Error bars represent standard deviations of invaded cells between different 
Matrigel invasion chambers. B) Number of DU-145 cells invaded during the Matrigel invasion assay. Error bars represent standard deviations of 
invaded cells between different Matrigel invasion chambers.     
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Figure 4: X-ray film developed from western blotting membrane. 
On the left there is molecular marker which shows the size of bands in kilodaltons (kDa). Arrows point the SnoN bands or places where SnoN 
band should be. There is western results from stable cell lines of DU-145 and RWPE-1 transfected with SKIL and control 
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6. DISCUSSION 
 
In this study we created cell lines with overexpression of SKIL and studied the 
functional differences between cells with or without SKIL overexpression. Previous 
studies carried out by our group have showed that there are some cases of prostate 
cancer where there is clear overexpression of SKIL but no overexpression of any ETS 
genes (Annala et al. 2015). Further studies showed that there is gene fusion between 
SKIL and TMPRSS2 genes. Earlier studies strongly suggest that SKIL has oncogenic 
features (Pearson-White et al. 1995, Sun et al. 1999, Liu et al. 2001, Imoto et al. 2001a, 
Chen et al. 2003, Buess et al. 2004, Reed et al. 2005, Deheuninck & Luo 2009, 
Hagerstrand et al. 2013). Also because there is no overexpression or fusion in ETS 
genes, which is common fusion gene in prostate cancer it seems likely that they don’t 
have any impact in progression of those cancers with SKIL fusion (Gasi Tandefelt et al. 
2014). Our study focused on the possible cancer driving role of SKIL in prostate cancer 
and in normal prostate cells. Although SKIL is known to be likely oncogene there are 
no evidence that it has any role in prostate cancer.  
 
According the previous studies SKIL has important role as inhibitor in TGF-β pathway. 
This pathway is known to be potent inhibitor of epithelial cell proliferation (Stroschein 
et al. 1999, Liu et al. 2001, Zhang et al. 2003, Deheuninck & Luo 2009). Inhibition of 
this pathway may be driving cause for developing of different cancers (Pearson-White 
et al. 1995, Stroschein et al. 1999, Liu et al. 2001). TGF-β is likely mechanistic 
explanation if overexpression of SKIL can induce cancer in prostate cells. Another 
recent study has proposed that SKIL can interact with and promote the activity of 
estrogen receptor α in the nuclei of breast carcinoma cells. This interaction can occur 
via two highly conserved nuclear receptor binding LxxLL-like motifs in SKIL (Band & 
Laiho 2012). This finding is intriguing as it suggests a potential interaction between 
SKIL and androgen receptor, as some LxxLL motifs have ability to bind with the ligand 
binding domain of AR (Dubbink et al. 2006).  
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6.1 Subcloning of SKIL 
 
As mentioned we failed to subclone the SKIL into empty pcDNA3.1(+) vector 
(Invitrogen). We tried many different solutions to this problem including changing the 
ratio of empty plasmid and SKIL gene, different gel isolation procedures and different 
bacterial cells (QIAquick Gel Extraction Kit (Qiagen) and GeneJET Gel Extraction Kit 
(Thermo scientific) were tried as gel extraction and One Shot® TOP10 chemically 
competent E. coli and NEB 5-alpha competent E. coli (New England Biolabs) were 
tried as competent cells). Also we made new agar plates for growing bacteria and also 
got new enzymes. Nothing of this worked so we decided to buy commercial plasmid 
with SKIL and control vector for that (pCI-Neo HA-hSnoN and pUNIV backbone from 
Addgene). There are some possible explanations which caused the failing of 
subcloning. One is the GC-rich zone in the SKIL, this provides problems in cloning and 
in PCR generally (Frey et al. 2008). Also we noticed afterwards that the patch of 
antibiotic which was used, might have been too old.          
 
6.2 Transfection of cell lines 
 
RWPE-1 and DU-145 cell lines were both transfected in order to create cell lines with 
stable overexpression of SKIL and cell lines with control stable control vectors. We 
wanted to create single cell clones with both of those cell lines. With DU-145 we 
managed to create several clones with stable transfection with SKIL or empty vector. 
When we tried to create single cell clone by using RWPE-1 cell line in same manner, 
we found out that these cells won’t start growing from single cell. This is however 
expected because RWPE-1 cells are created to mimic normal prostate cells (Webber et 
al. 1997). These prostate epithelial cells are usually not dividing so this also explains 
the problems in creating single cell clones (Frank & Miranti 2013). This lead us to 
conclusion that only option is to use cell pool with SKIL overexpression in case of the 
RWPE-1 cells.         
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6.3 Verification of SKIL overexpression by RT-qPCR 
 
Our goal was to make sure that there is significant overexpression of SKIL in mRNA 
level in all of the cell lines used. To do this we extracted total mRNA from all the cells 
and reverse transcribed it to cDNA using random hexamers. Then we used SKIL 
specific primers to perform qPCR to found out the relative SKIL mRNA levels of 
RWPE-1, DU-145 and PC-3 cells. Levels were compared in a way that cells with SKIL 
vector were compared with cells containing empty vector (e.g.no information about. 
expression levels between RWPE-1 and DU-145 cells). 
 
With DU-145 cells the overexpression between the clones was variable: we got some 
clones with quite high overexpression (about 10 times higher) and some clones have 
little or even nonexistent overexpression. This was expected because it is known that 
between single cell clones variance can be pretty high. We chose the clones with highest 
overexpression of SKIL in mRNA level. Although choosing the clones with highest 
expression is pretty standards procedure, one could argue that we are choosing only 
results which are good to us. To defend against that first thing to notice is the difference 
between cell pool and single cell clones. With cell pool we cannot be sure that every 
cell is identical in terms of expression levels of different genes and in our case 
specifically in terms of SKIL expression. With single cell clones we can be surer about 
the expression of genes to be more identical between cells. But when we then see 
expression differences between the different clones we cannot be sure what is causing 
the difference, this is why many clones are needed when using this kind of single cell 
clones. There are many potential reasons why expression levels of clones vary so much. 
Because all the cell are surviving in the environment with selection antibiotics, it is very 
likely that all the clones have the copy of the plasmid in them. So if we know that we 
have a vector in the cells and still there is no expression on explanation is that there is 
some problem with the plasmid. There can be problems for example with the promoter 
region of the gene of interest in our case with promoter of SKIL. Promoter region is 
likely region to be corrupted in some way because small changes in promoter region 
can cause big differences in expression levels of gene. CMV-promoter should be very 
strong promoter for protein expression in mammalian cells so changes there could 
indeed have effects for gene expression (Andersen et al. 2011). Number of plasmids 
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inside the cell is another factor which is not easy to control. If there is too many copies 
of the plasmid in the cell this can cause too much expression for the gene of interest.  
 
Of course it is possible that there are some mutations also in the gene of interest. This 
is however not that likely because even if there is some mutations in gene mRNA will 
still be transcribed and if mRNA is transcribed RT-qPCR should be able to detect this 
mRNA. So if there are mutations in gene itself they should be in the regions where 
primers used in the RT-qPCR should hybridize or the whole sequence between the 
primers used could be deleted. These are possible but unlikely scenarios which might 
explain some of the clones with no over expression but seems unlikely that they could 
explain all the cases. Of course it is possible that the whole gene has deleted from the 
vector and therefore there is no sign of overexpression. Reason why I think it is most 
likely that either there is no SKIL gene at all or there is some mutations which enable 
its promoter is the fact that expression levels are almost exactly the same as with the 
control clones. This indicates that the expression detected is coming from the cell’s own 
copy of the SKIL gene.  
 
It is known that too high expression of oncogene can cause apoptosis in cells (Lowe et 
al. 2004). So it is also possible that in some clones there were so high expression that it 
lead cells to apoptosis and so only the ones with low SKIL expression survived. Also 
there is mechanisms in cells which can lead to rapid mRNA degradation (Shim & Karin 
2002). This might also be the case in some of the clones. Epigenetic alterations in the 
plasmid could also cause the expression levels of SKIL to be similar with the control 
clones (Albany et al. 2011).   
 
 As said earlier, it is fair to say that clones have the vector in them, because they can 
survive in medium with geneticin. However there is possibility that some clones have 
created an ability to survive in medium with geneticin even without the geneticin 
resistance gene existing in the vector. This explanation however also seems unlikely, 
because human cells don’t have any genes which could be easily mutated to give 
geneticin resistance. It is possible that cells survive without resistance, but when taken 
account the concentration of geneticin (150 µg/ml during the selection and 100 µg/ml 
after that) there really shouldn’t be any cells like that.          
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As mentioned with RWPE-1 cells we weren’t able to create single cell clones because 
cells don’t survive the selection procedure. We got pretty nice overexpression in this 
cell pool (about 3 times higher in SKIL transfected), but the overexpression wasn’t as 
high as with the some of the single cell clones created using DU-145. Again there are 
several reasons which could explain this difference in expression differences between 
these two cell lines. First it is likely that because we have pool of cells the expression 
levels of individual cells differ more from each other than with the single cell clones. 
So with single cell clones we might get couple of clones with pretty high expression 
but with cell pool even if we have some cells with high expression levels we might lose 
this information because cells with somewhat lower expression levels bring the overall 
expression levels of pool lower.  
 
In addition to lower overall expression level we noticed that longer we kept growing 
the transfected RWPE-1 cells the lower was also the SKIL expression compared to cells 
transfected with empty vector. This change in expression during the time could not be 
seen in single cell clones made from DU-145 cells, although it is possible that it occur 
also there. With this kind of chance of expression during the time it is clear that this cell 
line is not that stabile after all. However right after stabilizing the cell line we created 
several cell ampules to storage in the liquid nitrogen. Right after we realized that there 
is change in expression levels of the cells we started using cells from the nitrogen in 
our experiments. These cells still had the same expression levels which were 
comparable with the ones detected right after cell pool was stabilized.  
 
Changes in the expression levels of course raise a question what is causing this. As 
mentioned there is probably cells with different expression levels within this cell pool. 
If high expression of SKIL causes some kind of growth disadvantage it means that there 
might be evolutional effects which cause the change in expression levels. Basically this 
means that cells with lower SKIL expression grow slightly faster. This causes the 
problem that every time cells are split there is little less cells with higher than average 
SKIL expression. If cells are being grown too long this eventually starts to affect the 
expression levels detected from the whole cell pool.  
 
Other possible explanation is that in the beginning there is not that much difference 
between the expression levels of different cells inside the RWPE-1 cell pool. Again if 
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over expression of SKIL causes some kind of growth disadvantage to the cells during 
the time then it is logical that cells will eventually somehow reduce the SKIL expression 
again because evolutional reasons (cells with original SKIL expression grow slower and 
are eliminated). I think however that the first option where cells have different 
expression to start with is more viable. I think so because with DU145 cells we can see 
that single cell clones have very different expression levels when compared with each 
other’s. If RWPE-1 cells act anything like that it seems logical to say that there is cells 
with expression levels clearly differing from each other’s.   
 
6.4 The effects of SKIL expression on the growth of the cell lines 
 
Increased growth rates can sometimes be detected when cells are transforming more 
towards the cancerous phenotype. We wanted to check if this happens with SKIL 
overexpression and with the cells we are using. However we already known from 
previous studies of the Hagerstrand et al. (2013) that they didn’t get increases growth 
rate when using immortalized human mammary epithelial cells with SKIL 
overexpression (Hagerstrand et al. 2013). However previously we knocked SKIL-
expression down in PC-3 cells using siRNAs (Annala et al. 2015). There we saw that 
SKIL inhibition decreased cell growth. This hints that SKIL might have role in cell 
growth also (Annala et al. 2015). 
 
Results from the DU-145 single cell clones showed no increased growth rate in clones 
with SKIL overexpression. Actually when looking the results it seems that control 
clones are the ones which grow little faster, but the difference is not statistically 
significant. It is not expected that overexpression actually slows the growth rates of the 
cells. There is not any obvious mechanism which could explain this slowed growth rate, 
but if the overexpression is really high this might already trigger some mechanisms 
which slow the growth of cells. That however shouldn’t be the case since 
overexpression is not that high in RT-qPCR. Because the difference is not statistically 
significant it may be that there is no real difference and no explanation is needed. 
Results are consistent with Hagerstrand et al. so in that sense these results are expected. 
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Results from RWPE-1 cell pool showed no increased growth rate in pool with SKIL 
overexpression. When comparing these two growth curves we can see that they are 
almost identical. There is little more deviation with SKIL overexpressing cell pool but 
nothing significant. We are missing results from day 3 because of failure in saving of 
the pictures taken on day 3. These results as the ones with the DU-145 are consistent 
with Hagerstrand et al. and they are expected.            
 
6.5 The effects of SKIL expression on the invasiveness of cell lines 
 
Although overexpression of SKIL didn’t have any effects on the growth rates of cells 
we wanted to see if it had some effects on the invasiveness of cells. In fact it would be 
more interesting if we had effects on invasiveness because it is usually considered to be 
stronger indicator of cancer causing abilities of the gene. Furthermore there is already 
another study which studied overexpression of SKIL in immortalized human mammary 
epithelial cells. Their study came to the conclusion that when expression levels of SKIL 
grow higher it doesn’t have any effect on the growth rate of the cells but instead 
increases the invasiveness capability of them (Hagerstrand et al. 2013). If the SKIL has 
similar effects on the prostate cells as in the mammary cells it seems likely that there 
should be changes in invasiveness although growth rates stayed the same.  
 
 Results from the matrigel invasion assay done with the DU-145 single cell clones 
showed high variation. We saw that ¾ clones showed no significant difference when 
compared to control in terms of invasion efficiency. There is one clone (clone A6) 
which showed significantly higher invasion efficiency than other clones. However there 
were also clone which (clone B3) had even lower invasion efficiency than control 
clones with empty vector. It is expected that there is variation between the clones. This 
could be already seen in the mRNA levels of SKIL. It seems reasonable to predict that 
highest invasiveness rates would be in the clones which show highest SKIL expression 
levels. However when looking at the results we see that this is not in fact the case.  
 
Explanation to this is not that easy to found. There could be some mechanisms which 
cause too high SKIL expression actually to decrease the invasiveness of cells, so the 
cells with little bit higher SKIL expression than the control cells would get invasiveness 
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advantage and the ones with even higher SKIL expression would again lose it. However 
there is not any, easy to find, well known mechanisms which supports this idea. It is 
also possible that these variations are due to some random factors that have nothing or 
little to do with the levels of SKIL expression. 
 
Results from the matrigel invasion assay done with the RWPE-1 cell pool showed more 
consistent results than ones with the DU-145 single cell clones. This is expected 
because DU-145 cells are aggressive and usually they harbor more random mutations 
which can cause the heterogeneity (Stone et al. 1978). We can see that cells which are 
overexpressing SKIL have significantly higher invasiveness rates than ones transfected 
with control vector. Results were expected and are consistent with (Hagerstrand et al. 
2013). However it is important to notice that number of cells which invaded through 
the matrigel are significantly lower with RWPE-1 cells than with the DU-145 cells (tens 
of cells in RWPE-1 versus thousands of cells with DU145). This can be explained by 
the fact that DU-145 cells are cancerous cells and RWPE-1 cells are not. Basically 
RWPE-1 cells should not invade at all (Bello et al. 1997). Cancer cells are usually more 
invasiveness than cells immortalized by other means and these results are consistent 
with that (Stone et al. 1978, Bello et al. 1997).  
 
Mechanism which causes this increase in invasiveness is not perfectly clear but it is 
likely that this happens due to increased inhibition in TGF-β pathway. There are couple 
of reasons which support this theory. First TGF-β pathway is best known target for the 
SKIL overexpression to have effects on. Also it is known that inhibition of TGF-β 
pathway has effects on the cell invasiveness (Liu et al. 2001, Deheuninck & Luo 2009). 
Controversially there is also some cell line as LNCaP which are induced comprehensive 
morphology changes by TGF-β signaling (Yang et al. 2014). Second evidence which 
supports the TGF-β pathway inhibition to be the mechanisms behind the increased 
invasiveness is results from the Hagerstrand et al. As mentioned before they showed 
that in immortalized human mammary epithelial cells SKIL overexpression induces 
invasion. Also they showed that SMAD4, which is the protein inhibited by the SKIL, 
when inhibited induces the same effect as SKIL overexpression (Hagerstrand et al. 
2013).    
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6.6 Western blotting 
 
Western blotting was carried out in purpose of verifying the SKIL overexpression also 
in protein level. This is important for us because our hypothesis predicts that SKIL 
overexpression may drive cancer development in cells via the TGF-β pathway. For this 
to be possible there should be more SKIL presence in protein level because only then it 
can bind to SMAD4 in increased rates and inhibit the TGF-β pathway. There are not 
any known mechanisms with SKIL mRNA to carry out so also in that sense there should 
be expression changes in protein level also. In their study Hagerstrand et al. were able 
to show SKIL overexpression in the immortalized human mammary epithelial cells also 
in protein level (Hagerstrand et al. 2013). 
 
Our results from both cell lines DU-145 and RWPE-1 showed no clear overexpression 
of SKIL in protein level. With both cell lines we can see that there are many bands 
which tells us that there has happened unspecific binding during the antibody 
incubations. However with both cell lines we can see that there is also band which 
represents the size SKIL should be. This predicts that antibody is able to bind right 
protein but it is unspecific and this leads to several bands seen in western blotting. We 
tried with two different antibodies and several different dilutions (1:4, 1:3, 1:2, 1:1 only 
Immunocruz and only SuperSignal®) with the Immunocruz Western Blotting Luminol 
Reagent SC-2018 (Santa Cruz) and SuperSignal® West Femto Maximum Sensitivity 
Substrate (Thermo Scientific). All results were similar in the sense that there were 
always unspecific bands present in the western blotting. Only time when amount of 
unspecific bands was low was when we used only Immunocruz Western Blotting 
Luminol Reagent SC-2018 (Santa Cruz) with short exposure time. This time however 
there were no clear bands representing SKIL (results not shown). We had had similar 
results with SKIL antibodies in our group before so it didn’t come as a surprise that this 
western blotting is problematic. 
 
The fact that we couldn’t show overexpression in protein level leaves us with some 
unanswered questions: there is change in phenotype of cells but is it due to SKIL? There 
is overexpression in mRNA level but is it enough to cause overexpression also in 
protein level? The reason why we can’t see the overexpression, or can’t even say with 
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confidence that there is none, is most likely the quality of antibodies. There is chance 
that problems are rising from some other source than antibody but in our lab there has 
been successful western blotting with same reagents so it doesn’t seem likely.  
 
6.7 Future perspectives 
 
Our goal was to create stable cell lines with SKIL overexpression and see the effects of 
SKIL overexpression in phenotype. We were able to get mRNA levels of SKIL up and 
got difference in the invasion levels of cells overexpressing SKIL and in control cells. 
We failed however to show this overexpression in protein level. First thing to do would 
be find a way to show the overexpression in protein level. One way to do that would be 
to create cell lines with more SKIL overexpression seen already in mRNA level. In our 
cells we got only about twice as high SKIL mRNA overexpression when compared to 
control cells. If these experiments would be repeated in the future we could use different 
prostate cancer cell lines or treat these cell lines with some cofactors to increase the 
gene expression. However there are not that many prostate cell lines so alternatives are 
limited. We could use non-prostate cell lines but that wouldn’t be that relevant. Other 
way of increasing the gene expression could be using lentiviral transduction in which 
lentiviruses are used as vectors when transforming cells. This should provide higher 
transfection efficiency and thus could increase the SKIL expression seen in cells 
compared to control cells. Other possible solutions are usage of different plasmid with 
different promoter or even the same plasmid but different promoter. At the moment 
plasmid has CMV promoter which is considered to be very strong promoter in 
mammalian cells (Andersen et al. 2011). However it is possible that this promoter is 
not that strong in cell lines used. This might be true with RWPE-1 cells as there is no 
articles clearly proving that CMV is a strong promoter in this cell line. With DU-145 
and PC-3 cells there is strong evidence that CMV promoter should create strong 
expression levels in the gene it is attached to (Zhang et al. 2002). When these facts are 
taken into consideration it seems unlikely that changing only the promoter would be 
enough to create higher expression in cell lines. Thus it seems more reasonable to 
believe that lentiviral transduction should be more efficient solution in this case since 
lentiviral expression system integrades gene in the genome itself. Also it would be 
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possible to use tet-off or tet-on system. This would allow us to turn gene expression on 
and measure the expression right away.  
 
In longer term it would be nice to be able to create in vivo model for the SKIL 
overexpression. This could be done using mice as it is standard model animal when 
studying prostate cancer. First thing to do with in vivo studies could be injection of 
LNCaP prostate cancer cells subcutaneously into nude mice. These LNCaP cells should 
first be transfected with plasmid overexpressing SKIL and other cells with control 
plasmid. Growth of the cancer could then be monitored during the period of time 
desired. This should provide us more information how SKIL effects development and 
growing of cancer in vivo. If this experiments provides positive results for the role of 
SKIL in cancer development mice experiments could be taken even further. It is possible 
to create mice lines which are genetically modified in the way that SKIL is 
overexpressed and this overexpression takes place only in the prostate. This should 
provide most reliable model for development of prostate cancer and through that it 
might be possible to understand the development in more detailed matter. For example 
it would be really interesting to find out gene expression levels in prostate before there 
is clear cancer development in prostate. This could provide us important information 
how this precise cancer develops. Also this can provide us information of gene 
expression levels of fully developed cancer. This is important, because if this SKIL 
overexpression represents new previously unknown subtype of prostate cancer, it helps 
us to recognize the expression patterns which can be found in real patience. This kind 
of studies leads us towards the personalized medicines and thus better treatment for 
prostate cancer.  
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7. CONCLUSION 
 
 
Our aim in this study was to create cell lines with stable overexpression of SKIL and 
analyze the effects of overexpression to cell’s phenotype. SKIL is potential prostate 
cancer inducing gene which was found earlier by our group. We transfected DU-145 
and RWPE-1 cells with plasmid containing SKIL-gene and control cells with empty 
vector. We cultured these cells with geneticin® (Gibco) to create stable transfections. 
Single cell clones were then created from DU-145 cells. After this we performed 
proliferation and invasion assays and also measured the mRNA and protein levels of 
SKIL. We wanted to see if overexpression of SKIL has effects on proliferation and 
invasion as these are typical qualities in cancer cells. 
 
Our results showed that it is possible for SKIL overexpression to induce different 
phenotype for cell lines used. We found out that proliferation is not changed in any of 
the cell lines but invasion effectivity of cells is changed. With RWPE-1 cells SKIL 
overexpression caused higher invasion rate. With DU-145 cells results were variable 
between the different clones. This indicates that it is be possible that SKIL 
overexpression alone could induce prostate cancer growth. However we could not get 
a clear SKIL overexpression in protein level and this leaves questions about mechanisms 
which cause the phenotype. Further investigations needs to be carried out to find out 
precise functions of SKIL and it’s overexpression in prostate cancer. We need to find 
precise gene expression patterns caused by SKIL overexpression. However these studies 
already suggest that there is link between SKIL and cancer also this provides good 
foundation and starting point for further studies concerning SKIL.   
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9. APPENDIX 
 
 
 
Appendix picture 1: Relative mRNA expression levels of SKIL. 
The expression of SKIL mRNA in PC-3 cells transfected with either of two different 
SKIL siRNAs or with control siRNA. Error bars represent standard deviations of RT-
qPCR replicates. 
 
